• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Axcellerate Pharma to open CRO/CMO in New Jersey

Axcellerate Pharma to open CRO/CMO in New Jersey

November 25, 2013
CenterWatch Staff

CRO Axcellerate Pharma is establishing a CMO/CRO and API manufacturing facility in New Jersey that will focus on small molecule and biologics PR&D, innovative technology platforms, filling vial and bag operations, peptide synthesis, oligonucleotide production and related areas.

Axcellerate Pharma is a joint venture set up by CRO TCG Lifesciences USA, with Dilip Mehta, founder and CEO of Panorama Consulting and Engineering, a developer of lab scale to GMP manufacturing facilities, and Alfagen Pharma, an affiliate of biotech AlfaGene Bioscience. The facility houses technology, equipment and infrastructure.

"We will initially target specialized CMC and CMO activities that are time sensitive and high value in nature, that are desirable to be located geographically close to our clients,” said Swapan Bhattacharya, managing director of TCG Lifesciences. Axcellerate plans to leverage its scientific talent pool, end-to-end capabilities and the PR&D/intermediate production facilities of TCG Lifesciences in India to support its operations. The alliance expands TCG Lifesciences’ geographic footprint and enable the company to serve clients in the U.S. with a local presence.

“AlfaGene Bioscience has developed proprietary assay platforms in a range of therapeutic indications and has a scientific team with extensive experience in biologics and biomedical research,” said Mayur Doshi, president and CEO, AlfaGene Bioscience.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing